| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ... The American Journal of Human Genetics 72 (5), 1117-1130, 2003 | 4716 | 2003 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ... The Lancet 376 (9737), 235-244, 2010 | 2158 | 2010 |
| Gene-expression profiles in hereditary breast cancer I Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ... New England Journal of Medicine 344 (8), 539-548, 2001 | 2154 | 2001 |
| Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ... Journal of clinical oncology 33 (3), 244-250, 2014 | 1897 | 2014 |
| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ... The Lancet 376 (9737), 245-251, 2010 | 1674 | 2010 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The Lancet Oncology 18 (12), 1688-1700, 2017 | 640 | 2017 |
| Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ... Jama 313 (13), 1347-1361, 2015 | 547 | 2015 |
| An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression A Palazon, PA Tyrakis, D Macias, P Veliça, H Rundqvist, S Fitzpatrick, ... Cancer cell 32 (5), 669-683. e5, 2017 | 406 | 2017 |
| A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general … AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ... Nature genetics 42 (10), 885, 2010 | 406 | 2010 |
| Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer N Loman, O Johannsson, U Kristoffersson, H Olsson, A Borg Journal of the National Cancer Institute 93 (16), 1215-1223, 2001 | 356 | 2001 |
| Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS genetics 9 (3), e1003212, 2013 | 328 | 2013 |
| Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ... Gynecologic oncology 140 (2), 199-203, 2016 | 302 | 2016 |
| Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors M Laakso, N Loman, Å Borg, J Isola Modern pathology 18 (10), 1321, 2005 | 268 | 2005 |
| Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics G Jönsson, J Staaf, J Vallon-Christersson, M Ringnér, K Holm, C Hegardt, ... Breast Cancer Research 12 (3), R42, 2010 | 251 | 2010 |
| Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene H Persson, A Kvist, N Rego, J Staaf, J Vallon-Christersson, L Luts, ... Cancer research 71 (1), 78-86, 2011 | 248 | 2011 |
| Molecular classification of familial non-BRCA1/BRCA2 breast cancer I Hedenfalk, M Ringnér, A Ben-Dor, Z Yakhini, Y Chen, G Chebil, R Ach, ... Proceedings of the National Academy of Sciences 100 (5), 2532-2537, 2003 | 248 | 2003 |
| Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial O Bjarnadottir, Q Romero, PO Bendahl, K Jirström, L Rydén, N Loman, ... Breast cancer research and treatment 138 (2), 499-508, 2013 | 239 | 2013 |
| Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer. S Håkansson, O Johannsson, U Johansson, G Sellberg, N Loman, ... American journal of human genetics 60 (5), 1068, 1997 | 225 | 1997 |
| Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes N Loman, O Johannsson, PO Bendahl, Å Borg, M Fernö, H Olsson Cancer 83 (2), 310-319, 1998 | 223 | 1998 |
| Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome J Staaf, M Ringnér, J Vallon-Christersson, G Jönsson, PO Bendahl, ... Journal of Clinical Oncology 28 (11), 1813-1820, 2010 | 219 | 2010 |
